Gzide 60mg Tablet XR contains Gliclazide, a sulfonylurea class oral hypoglycemic agent indicated for the management of type 2 diabetes mellitus. This extended-release formulation provides a controlled and sustained release of gliclazide, promoting prolonged glycemic control throughout the day with once-daily dosing. Gliclazide acts primarily by stimulating insulin secretion from pancreatic beta cells, thereby lowering blood glucose levels. It is particularly useful in patients whose diabetes is inadequately controlled by diet and exercise alone. Gzide 60mg Tablet XR should be used as part of a comprehensive diabetes management plan, including dietary modifications and regular physical activity. The extended-release mechanism helps minimize fluctuations in plasma drug concentration, reducing the risk of hypoglycemia compared to immediate-release formulations. Dosage should be individualized based on patient response, renal function, and glycemic targets, with careful monitoring of blood glucose levels to avoid hypoglycemia. Contraindications include type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and allergic reactions. Gzide 60mg Tablet XR is a valuable therapeutic option for improving glycemic control and reducing the risk of diabetes-related complications in type 2 diabetic patients.